

# Adam M Sonabend

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/378791/publications.pdf>

Version: 2024-02-01

72  
papers

2,925  
citations

186265  
28  
h-index

189892  
50  
g-index

79  
all docs

79  
docs citations

79  
times ranked

4587  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of preoperative embolization in the treatment of spinal metastases from renal cell carcinoma. <i>Clinical Neurology and Neurosurgery</i> , 2022, 215, 107181.	1.4	5
2	Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 3156-3169.	7.0	4
3	Abstract 2548: The central nervous system immune cell interactome is a function of cancer lineage, tumor microenvironment and STAT3 expression. <i>Cancer Research</i> , 2022, 82, 2548-2548.	0.9	0
4	Management of glioblastoma: a perspective from Mexico. <i>Chinese Clinical Oncology</i> , 2021, 10, 1-1.	1.2	2
5	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2021, 27, 1766-1777.	7.0	38
6	Role of Resection in Glioblastoma Management. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 9-22.	1.7	14
7	Risk Factors for Transverse Ligament Disruption and Vertebral Artery Injury Following an Atlas Fracture. <i>World Neurosurgery</i> , 2021, 146, e1345-e1350.	1.3	12
8	Activation of 4-1BBL+ B cells with CD40 agonism and IFN $\gamma$ elicits potent immunity against glioblastoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	42
9	Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy. <i>Oncotarget</i> , 2021, 12, 8-9.	1.8	2
10	A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	136
11	Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. <i>Journal of Neurosurgery</i> , 2021, 134, 1357-1367.	1.6	31
12	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 5669-5680.	7.0	4
13	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. <i>Lancet Oncology</i> , <i>The</i> , 2021, 22, 1103-1114.	10.7	91
14	Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas. <i>Oncotarget</i> , 2021, 12, 2474-2475.	1.8	6
15	BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi17-vi17.	1.2	0
16	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	18.2	39
17	BIOM-32. ENDOPLASMIC RETICULUM PROTEIN SSR3 DETERMINES AND PREDICTS RESPONSE TO PACLITAXEL IN BREAST CANCER AND GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi17-vi18.	1.2	0
18	Ultrasound-mediated Blood-brain barrier opening increases cell-free DNA in a time dependent manner. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab165.	0.7	5

#	ARTICLE	IF	CITATIONS
19	The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13382.	4.1	14
20	Uncertainty in the Relationship Between Sagittal Alignment and Patient-Reported Outcomes. <i>Neurosurgery</i> , 2020, 86, 485-491.	1.1	9
21	Evaluation of patient education materials for stereotactic radiosurgery from high-performing neurosurgery hospitals and professional societies. <i>Neuro-Oncology Practice</i> , 2020, 7, 59-67.	1.6	3
22	Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. <i>Clinical Cancer Research</i> , 2020, 26, 477-486.	7.0	98
23	Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 61-64.	1.5	3
24	Trends in national utilization of posterior lumbar fusion and 30-day reoperation and readmission rates from 2006–2016. <i>Clinical Neurology and Neurosurgery</i> , 2020, 199, 106310.	1.4	8
25	CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. <i>Clinical Cancer Research</i> , 2020, 26, 4390-4401.	7.0	36
26	Ribosomal protein S11 influences glioma response to TOP2 poisons. <i>Oncogene</i> , 2020, 39, 5068-5081.	5.9	21
27	Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 4699-4712.	7.0	65
28	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. <i>Neuro-Oncology</i> , 2020, 22, 1425-1438.	1.2	37
29	Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma. <i>British Journal of Neurosurgery</i> , 2020, 34, 690-696.	0.8	10
30	LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). <i>Neuro-Oncology</i> , 2020, 22, ii237-ii237.	1.2	21
31	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. <i>Journal of Neurosurgery</i> , 2020, 132, 1667-1672.	1.6	10
32	Immunopathology and Immunotherapy of Central Nervous System Cancer. , 2020, , 379-425.		0
33	Extent of resection and survival for oligodendroglioma: a U.S. population-based study. <i>Journal of Neuro-Oncology</i> , 2019, 144, 591-601.	2.9	45
34	Immunotherapy Against Gliomas: is the Breakthrough Near?. <i>Drugs</i> , 2019, 79, 1839-1848.	10.9	10
35	Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2019, 143, 457-464.	2.9	14
36	Overcoming the Blood–Brain Barrier with an Implantable Ultrasound Device. <i>Clinical Cancer Research</i> , 2019, 25, 3750-3752.	7.0	18

#	ARTICLE	IF	CITATIONS
37	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	30.7	569
38	Craniotomy and Survival for Primary Central Nervous System Lymphoma. <i>Neurosurgery</i> , 2019, 84, 935-944.	1.1	46
39	A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3012-3012.	1.6	30
40	Newly Diagnosed Glioblastoma: A Review on Clinical Management. <i>Oncology</i> , 2019, 33, 91-100.	0.5	42
41	The possibility of cancer immune editing in gliomas. A critical review. <i>Oncolmmunology</i> , 2018, 7, e1445458.	4.6	35
42	Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases. <i>CNS Oncology</i> , 2018, 7, 25-34.	3.0	9
43	Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study. <i>Journal of Neuro-Oncology</i> , 2018, 138, 173-182.	2.9	59
44	Predictors of Readmissions and Reoperations Related to Venous Thromboembolic Events After Spine Surgery: A Single-Institution Experience with 6869 Patients. <i>World Neurosurgery</i> , 2018, 111, e91-e97.	1.3	16
45	Outcomes of thoracic discectomy: A single center retrospective series. <i>Journal of Clinical Neuroscience</i> , 2018, 48, 128-132.	1.5	0
46	Online Ratings of Neurosurgeons. <i>Neurosurgery</i> , 2018, 83, 1143-1152.	1.1	19
47	Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. <i>Frontiers in Neurology</i> , 2018, 9, 459.	2.4	18
48	Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm. <i>Nature Communications</i> , 2018, 9, 1471.	12.8	95
49	Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study. <i>Neurosurgery</i> , 2017, 80, 590-601.	1.1	34
50	The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2017, 132, 189-197.	2.9	25
51	Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2017, 133, 409-417.	2.9	14
52	Timing and risks of chemoprophylaxis after spinal surgery: a single-center experience with 6869 consecutive patients. <i>Journal of Neurosurgery: Spine</i> , 2017, 27, 681-693.	1.7	28
53	Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 191-201.	0.8	11
54	Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development. <i>Journal of Neuro-Oncology</i> , 2017, 134, 453-463.	2.9	16

#	ARTICLE	IF	CITATIONS
55	Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A Nationwide Inpatient Sample Analysis. <i>Frontiers in Neurology</i> , 2017, 8, 478.	2.4	13
56	Monitoring Radiation Treatment Effects in Glioblastoma: FLAIR Volume as Significant Predictor of Survival. <i>Tomography</i> , 2017, 3, 131-137.	1.8	15
57	Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection. <i>Archives in Cancer Research</i> , 2016, 4, .	0.3	18
58	Microsurgical resection of pineal region tumors. <i>Journal of Neuro-Oncology</i> , 2016, 130, 351-366.	2.9	63
59	Frailty in Geriatric Glioblastoma Patients: A Predictor of Operative Morbidity and Outcome. <i>World Neurosurgery</i> , 2016, 89, 362-367.	1.3	98
60	Venous air embolus during scalp incision. <i>Journal of Clinical Neuroscience</i> , 2016, 28, 170-171.	1.5	3
61	Boosting Dendritic Cell Vaccination for Glioblastoma Using Tetanus Toxoid. <i>Neurosurgery</i> , 2015, 77, N20-N21.	1.1	0
62	The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma. <i>World Neurosurgery</i> , 2015, 84, 913-919.	1.3	44
63	Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1210-1219.	1.2	34
64	The Transcriptional Regulatory Network of Proneural Glioma Determines the Genetic Alterations Selected during Tumor Progression. <i>Cancer Research</i> , 2014, 74, 1440-1451.	0.9	48
65	Management Paradigms Along a Histologic Spectrum of Pineal Cell Tumors. <i>World Neurosurgery</i> , 2014, 81, 685-687.	1.3	3
66	Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. <i>Neuro-Oncology</i> , 2014, 16, 779-786.	1.2	77
67	Murine cell line model of proneural glioma for evaluation of anti-tumor therapies. <i>Journal of Neuro-Oncology</i> , 2013, 112, 375-382.	2.9	36
68	Prevention of Ventriculostomy-Related Infections With Prophylactic Antibiotics and Antibiotic-Coated External Ventricular Drains: A Systematic Review. <i>Neurosurgery</i> , 2011, 68, 996-1005.	1.1	110
69	Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. <i>Neuro-Oncology</i> , 2011, 13, 886-893.	1.2	56
70	Glioblastoma Models Reveal the Connection between Adult Glial Progenitors and the Proneural Phenotype. <i>PLoS ONE</i> , 2011, 6, e20041.	2.5	129
71	Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma. <i>Stem Cells</i> , 2008, 26, 831-841.	3.2	226
72	Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4